Loading…
Greenwich LifeSciences, Inc. is projected to rise to $17.33 by 2027, a +28% move from its current price of $13.50. GLSI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $12.77 | $13.49 | $14.25 | -0.07% |
| Aug 4 | $12.47 | $13.48 | $14.57 | -0.14% |
| Aug 5 | $12.25 | $13.47 | $14.82 | -0.20% |
| Aug 6 | $12.06 | $13.46 | $15.03 | -0.27% |
| Aug 7 | $11.90 | $13.45 | $15.21 | -0.34% |
| Aug 8 | $11.75 | $13.45 | $15.38 | -0.41% |
| Aug 9 | $11.62 | $13.44 | $15.54 | -0.47% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.62 | $13.44 | $15.54 | -0.47% |
| Week 2 | $10.89 | $13.37 | $16.42 | -0.94% |
| Week 3 | $10.35 | $13.31 | $17.12 | -1.41% |
| Week 4 | $9.91 | $13.25 | $17.72 | -1.88% |
| Week 5 | $9.53 | $13.18 | $18.25 | -2.34% |
| Week 6 | $9.19 | $13.12 | $18.73 | -2.80% |
| Week 7 | $8.89 | $13.06 | $19.18 | -3.26% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company that develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product GP2 is a HER2/neu transmembrane peptide that is in Phase III clinical trial to prevent breast cancer recurrences.
The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc.
and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
This description places Greenwich LifeSciences in the Healthcare sector, reflecting its focus on oncology therapies and clinical-stage development activities in the United States.
Greenwich LifeSciences, Inc. (GLSI) trades at $14.02 per share and has a market capitalization of $205.79M, with a rank of 3562. The stock’s price action is currently characterized by a price level below key moving averages, signaling a nuanced near-term setup.
The technical picture shows the SMA50 at $21.23 and the SMA200 at $20.21, with the current price at $14.02 trading beneath both averages. Support is identified at $12.80 and resistance at $23.99, with the 30-day price range spanning $9.68 to $20.30. Annualized volatility is 100%, underscoring elevated swings in this equity.
Forecasts for the coming years depict a rising trajectory from 2026 through 2050, with 2026 showing an average price of $14.02 and progressively higher averages thereafter, culminating in a 2050 average of $62.43 and a max of $143.58. The implied returns show a bullish tilt from 2027 onward, with long-run upside potential and substantial variability depending on market and regulatory factors.
A major floor 57.5% below — a decisive break under it would weaken the trend.
The nearest floor, 5.2% below — buyers have tended to step in here.
The nearest ceiling, 75.9% above — a clean break opens room to run.
A major ceiling 116.5% above — clearing it would confirm fresh momentum.
Key GLSI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GLSI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.44 | Buy | $13.57 | Sell |
| MA 10 | $13.54 | Sell | $14.24 | Sell |
| MA 20 | $16.25 | Sell | $16.01 | Sell |
| MA 50 | $20.97 | Sell | $19.34 | Sell |
| MA 100 | $22.91 | Sell | $20.93 | Sell |
| MA 200 | $20.23 | Sell | $20.02 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.42 | Neutral |
| Stoch RSI (14) | 43.47 | Neutral |
| CCI (20) | -67.57 | Neutral |
| Williams %R (14) | -89.61 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -30.91 | Sell |
| Bollinger %B (20,2) | 0.26 | Neutral |
| Stochastic %K (14) | 10.39 | Buy |
| TRIX (15) | -1.63 | Sell |
| Awesome (5,34) | -5.46 | Sell |
| Ultimate (7,14,28) | 43.37 | Neutral |
| Momentum (10) | -2.82 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 13.46 | Buy |
| ADX (14) | 27.94 | Sell |
| ATR (14) | 0.88 | Info |
The near-term technical picture is neutral, with RSI(14) at 40. This sentiment aligns with a price that is currently below the major moving averages, as the SMA50 is $21.23 and the SMA200 is $20.21.
Price action is confined by a 30-day range between $9.68 and $20.30, while support sits at $12.80 and resistance sits at $23.99. These levels give a sense of the critical boundaries for the coming month, emphasizing caution around a potential breakout above the $23.99 resistance.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.80 | $13.50 | $17.34 | 0% | Neutral | |
| $12.62 | $17.33 | $25.71 | +28% | Bullish | |
| $14.34 | $20.93 | $33.14 | +55% | Bullish | |
| $13.67 | $21.03 | $34.97 | +56% | Bullish | |
| $14.21 | $22.93 | $39.71 | +70% | Bullish | |
| $11.90 | $20.07 | $35.98 | +49% | Bullish | |
| $10.96 | $19.28 | $35.65 | +43% | Bullish | |
| $12.01 | $22.01 | $41.84 | +63% | Bullish | |
| $13.19 | $25.13 | $48.99 | +86% | Bullish | |
| $16.55 | $32.79 | $65.41 | +143% | Bullish | |
| $15.46 | $34.35 | $75.34 | +154% | Bullish | |
| $25.33 | $56.29 | $129.47 | +317% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $12.80 | $13.50 | $16.09 | +0.00% |
| September 2026 | $10.99 | $13.37 | $16.98 | -0.95% |
| October 2026 | $10.29 | $12.69 | $16.44 | -5.08% |
| November 2026 | $9.59 | $11.96 | $15.74 | -5.77% |
| December 2026 | $10.30 | $12.98 | $17.34 | +8.55% |
Click any year to see its month-by-month GLSI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, GLSI could reach as high as $17.34, with a base case around $13.50 and support toward $12.80 — roughly 0% from $13.50. Price action looks broadly range-bound.
Expect GLSI to range from $12.62 to $25.71 through 2027. The $17.33 average target implies a +28% move from current prices. That is up +28% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The GLSI price prediction for 2028 points to an average of $20.93 (low $14.34, high $33.14) — a potential gain of +55% on today's $13.50. Momentum favours further upside here.
In 2029, GLSI is projected to trade between $13.67 and $34.97, averaging $21.03 — a potential gain of +56% from today's $13.50. That is up 0% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Greenwich LifeSciences, Inc.'s 2030 outlook centres on $22.93, within a $14.21 to $39.71 range. That is up +9% on the projected 2029 average. That marks a +70% change versus current levels. Momentum favours further upside here.
By 2031, GLSI could reach as high as $35.98, with a base case around $20.07 and support toward $11.90 — roughly +49% from $13.50. Buyers look set to stay in control over this stretch.
Expect GLSI to range from $10.96 to $35.65 through 2032. The $19.28 average target implies a +43% move from current prices. That is -4% versus the projected 2031 average. Momentum favours further upside here.
The GLSI price prediction for 2033 points to an average of $22.01 (low $12.01, high $41.84) — a potential gain of +63% on today's $13.50. Buyers look set to stay in control over this stretch.
In 2034, GLSI is projected to trade between $13.19 and $48.99, averaging $25.13 — a potential gain of +86% from today's $13.50. That is up +14% on the projected 2033 average. Momentum favours further upside here.
Greenwich LifeSciences, Inc.'s 2035 outlook centres on $32.79, within a $16.55 to $65.41 range. That is up +30% on the projected 2034 average. That marks a +143% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, GLSI could reach as high as $75.34, with a base case around $34.35 and support toward $15.46 — roughly +154% from $13.50. Momentum favours further upside here.
Expect GLSI to range from $25.33 to $129.47 through 2050. The $56.29 average target implies a +317% move from current prices. That is up +64% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in GLSI today (≈ 74.074074 GLSI) could be worth
$4,169.67
+$3,169.67 (+317%) by 2050 · US Dollar
Based on the average projected GLSI price of $56.29 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GLSIwould be worth at today's price.
$1,000 invested in GLSI on Jul 31, 2025 (≈ 91.407682 GLSI) would be worth
$1,234
+$234 (+23.4%) today · 1.23× · US Dollar
Based on a GLSI entry price of $10.94 vs. today's $13.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.98 | $1,040.06 | +4.0% |
| 1 month ago | $23.7 | $569.62 | -43.0% |
| 3 months ago | $23.7 | $569.62 | -43.0% |
| 6 months ago | $31.97 | $422.27 | -57.8% |
| 1 year ago | $10.94 | $1,234 | +23.4% |
| All time (5.0y) ago | $39.99 | $337.58 | -66.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GLSI forecast.
Our base-case forecast reaches $27.00 around 2035.
Implied market cap at $27.00: $396.31M
The multi-year forecast points to a bullish trajectory with steadily higher averages across the years. In 2027 the average is $18.51, rising further in 2028 to $22.47 and in 2029 to $22.52, with all three years shown as bullish.
In 2030 the forecast shows an average of $24.50 and a max of $42.44, with a 74.8 return profile and bullish sentiment. By 2040 the average is projected at $38.35 with a max of $84.11 and a 173.5 return, continuing the bullish trend. In 2050 the forecast peaks at an average of $62.43 and a max of $143.58, with a 345.3 return and bullish sentiment.
These numbers illustrate meaningful upside potential over the long term, but they are estimates and not guarantees. Upside depends on clinical outcomes, regulatory approvals, and broader market conditions.
Tap a question to reveal the answer.
In 2030 the forecast shows a min of $15.18, an avg of $24.50, and a max of $42.44, with a forecasted ROI of 74.8 and a bullish sentiment.
The long-run forecast is bullish from 2027 onward, with expected average prices rising to $18.51 (2027), $24.50 (2030), and $62.43 (2050), and ROI reaching 32.1 in 2027, 74.8 in 2030, and 345.3 by 2050. These are estimates, not guarantees, and actual results will vary.
No. The 2030 max in the forecast is $42.44, which is below $50. Reaching $50 appears possible in later years, e.g., the 2034 max is $54.11 and the 2035 max is $71.88.
The current price is $14.02 and the market cap is $205.79M. The stock rank is 3562.
Sentiment is NEUTRAL with RSI(14) at 40. The price is below the SMA50 of $21.23 and the SMA200 of $20.21, with a 30-day range of $9.68–$20.30, support at $12.80, and resistance at $23.99.
Greenwich LifeSciences, Inc. Community Discussion
0Share your Greenwich LifeSciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.